HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Direct Sales Industry Guidance Responds To ‘Increase In Questionable Earnings Claims’

Executive Summary

Direct Selling Self-Regulatory Council and Direct Selling Association guidance aims to curb multi-level marketers’ misleading earnings claims, a practice increasing among health and wellness direct sellers during the COVID-19 pandemic.

You may also be interested in...



Direct Seller’s Data Counters FTC’s Pyramid Scheme Complaint Based On ‘Assumption’ About Sales

Ruling in Texas federal court on FTC complaint against Neora could serve as instructions for agency on how not to prosecute pyramid scheme allegations and for direct sellers about operating businesses so regulators find no hint of sales associates’ compensation plans based more on recruiting additional participants than on selling products.

NAD Simplifies, Lowers Fees For Disclosure Challenges In SWIFT Ad Claim Reviews

National Advertising Division streamlined the process for submitting SWIFT challenges about disclosure claims and lowered the filing fee for the challenges. Growing use of testimonials, “influencer” marketing prompted change.

People On The Move: Appointments At Stada, CHPA, Valbiotis And DSA

The latest global health and wellness industry appointments: Stada hires Uriach's Roura to lead Spanish OTC business; CHPA elects J&J's Goodridge; Valbiotis brings in Ipsen's Bessy; and Mannatech's Bala joins DSA's board.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel